Google
NRSNW 株価分析 — Neurosense Therapeutics LTD. Warrant
NRSNW に関するよくある質問
NRSNWのROE（自己資本利益率）は？
Neurosense Therapeutics LTD. WarrantのROEは713.14%です。
NRSNWの配当利回りは？
Neurosense Therapeutics LTD. Warrantの配当利回りは0.00%です。
NRSNWの品質スコア（Quality Score）は？
当社のAIはNRSNWの総合財務品質を100点中46点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
NRSNWは今が買い時ですか？
当社AIのタイミングスコアは100点中1点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
NRSNW AI Analysis Summary
Our AI summary for NRSNW: Neurosense Therapeutics LTD. Warrant (NASDAQ). The stock currently trades at a P/E of 0.00, ROE of 713.14%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 1/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.12
Price
-0.04
(-25.77%)
Day Change
|
|
|---|
NRSNW, ファンダメンタルスコアはnot good ( ファンダメンタル = 46) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROAが低い
ROEの伸びが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 97 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.12 |
| PBV / Sector |
-1.94 / N/A
|
| Earning Per Share | -0.44 |
| PE / Sector |
N/A / N/A
|
| PEG or PE/Growth / Sector |
N/A / N/A
|
| Average 1M Daily Value |
167.470940000000
|
| Average 1W Daily Value |
143.442880000000
|
| Timing Factors |
|
57% |
| Financial Health |
|
37% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Building B, Herzliya, Israel, 4672562
Phone: 972 9 799 6183
Website: https://www.neurosense-tx.com
Sector: -
Description: NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
